Menendez, C.A.; Mohamed, A.; Perez-Lemus, G.R.; Weiss, A.M.; Rawe, B.W.; Liu, G.; Crolais, A.E.; Kenna, E.; Byléhn, F.; Alvarado, W.;
et al. Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity. Molecules 2023, 28, 6643.
https://doi.org/10.3390/molecules28186643
AMA Style
Menendez CA, Mohamed A, Perez-Lemus GR, Weiss AM, Rawe BW, Liu G, Crolais AE, Kenna E, Byléhn F, Alvarado W,
et al. Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity. Molecules. 2023; 28(18):6643.
https://doi.org/10.3390/molecules28186643
Chicago/Turabian Style
Menendez, Cintia A., Adil Mohamed, Gustavo R. Perez-Lemus, Adam M. Weiss, Benjamin W. Rawe, Guancen Liu, Alex E. Crolais, Emma Kenna, Fabian Byléhn, Walter Alvarado,
and et al. 2023. "Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity" Molecules 28, no. 18: 6643.
https://doi.org/10.3390/molecules28186643
APA Style
Menendez, C. A., Mohamed, A., Perez-Lemus, G. R., Weiss, A. M., Rawe, B. W., Liu, G., Crolais, A. E., Kenna, E., Byléhn, F., Alvarado, W., Mendels, D., Rowan, S. J., Tay, S., & de Pablo, J. J.
(2023). Development of Masitinib Derivatives with Enhanced Mpro Ligand Efficiency and Reduced Cytotoxicity. Molecules, 28(18), 6643.
https://doi.org/10.3390/molecules28186643
